CTLA4 and neoplasm: Recently, a number of preclinical investigations have demonstrated that the efficacy of CTLA-4 antibody drugs relies on the elimination of Treg cells within the tumor, facilitated by the antibody’s heavy chain constant region Fc and immune cell Fc receptors (104, 105).